Grupp L A, Lau V, Harding S
Biobehavioral Research Department, Addiction Research Foundation of Ontario, University of Toronto, Canada.
Psychopharmacology (Berl). 1998 Jul;138(2):167-75. doi: 10.1007/s002130050659.
Many adrenergic agonists including isoproterenol, a beta1,2-adrenergic agonist, reduce alcohol consumption, but the mechanism of this effect is not known. Adrenergic agonists have a variety of effects, among which are their ability to raise both angiotensin (ANG) II activity and plasma glucose levels. Previous research has shown that ANG II and enhanced glucose levels are accompanied by reductions in alcohol intake. Therefore, the following experiments assessed the roles of each of these factors in the suppression of alcohol intake by isoproterenol. Male Wistar rats were trained to drink a quantity of 6% (w/v) alcohol using the limited access procedure, which offers a daily 40-min access to alcohol and water. In experiment 1, isoproterenol or vehicle was administered s.c. just prior to alcohol availability, and only the group receiving isoproterenol showed a marked reduction in alcohol intake. Following this, the groups were pretreated i.p. with either vehicle or ascending doses of the prostaglandin synthetase inhibitor, indomethacin (2, 4 mg/kg), followed by either isoproterenol or vehicle. Control groups received either two vehicle injections or vehicle and indomethacin. Indomethacin alone did not affect alcohol intake at any of the doses tested but did dose-dependently attenuate the reduction in alcohol intake produced by isoproterenol. In experiment 2, isoproterenol was administered just prior to alcohol availability and when the suppression of alcohol intake stabilized, ascending doses of the angiotensin converting enzyme inhibitor, enalapril (1, 20, 40 mg/kg), were given i.p. 1 h prior to the isoproterenol. Enalapril altered water intake but had no effect on the isoproterenol-induced reduction in alcohol intake. These results show that the inhibition of alcohol drinking by isoproterenol varies more closely with altered glucose levels than with increased ANG II synthesis. They also demonstrate that downstream consequences of a drug may play a role in its effect on alcohol intake.
许多肾上腺素能激动剂,包括β1、2肾上腺素能激动剂异丙肾上腺素,都能减少酒精摄入量,但其作用机制尚不清楚。肾上腺素能激动剂有多种作用,其中包括提高血管紧张素(ANG)II活性和血浆葡萄糖水平的能力。先前的研究表明,ANG II和血糖水平升高伴随着酒精摄入量的减少。因此,以下实验评估了这些因素各自在异丙肾上腺素抑制酒精摄入中的作用。雄性Wistar大鼠通过限时获取程序接受训练,饮用一定量的6%(w/v)酒精,该程序每天提供40分钟的酒精和水获取时间。在实验1中,在酒精可得之前皮下注射异丙肾上腺素或赋形剂,只有接受异丙肾上腺素的组酒精摄入量显著减少。在此之后,给各组腹腔注射赋形剂或递增剂量的前列腺素合成酶抑制剂吲哚美辛(2、4mg/kg),随后注射异丙肾上腺素或赋形剂。对照组接受两次赋形剂注射或赋形剂与吲哚美辛。单独使用吲哚美辛在任何测试剂量下均不影响酒精摄入量,但确实剂量依赖性地减弱了异丙肾上腺素引起的酒精摄入量减少。在实验2中,在酒精可得之前注射异丙肾上腺素,当酒精摄入量的抑制稳定后,在注射异丙肾上腺素前1小时腹腔注射递增剂量的血管紧张素转换酶抑制剂依那普利(1、20、40mg/kg)。依那普利改变了水的摄入量,但对异丙肾上腺素诱导的酒精摄入量减少没有影响。这些结果表明,异丙肾上腺素对酒精饮用的抑制与血糖水平的改变比与ANG II合成增加的关系更为密切。它们还表明,药物的下游后果可能在其对酒精摄入量的影响中起作用。